Goldman Sachs adds Biogen to Conviction Buy List
Biogen Inc. (BIIB) is up 1.4% Wednesday morning. The stock was already rated a “buy” at Goldman Sachs, but the research firm added it to its Conviction Buy List. Goldman has a $338 price target on the stock.
Biogen Inc. (BIIB) is a biotech company.
Urban Outfitters, Inc. (URBN) and Target Corporation (TGT) top the list of other companies with positive news today, while Chicago Bridge & Iron Company N.V. (CBI) and Teva Pharmaceutical Industries Limited (TEVA) top the list of companies with negative news.
Already a member?
Login to see your Morning News Leader Trade Idea.
Not yet a member?
You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.
Become A Member
About Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.